CFTR and cystic fibrosis: Rapid developments in genomeediting technology leave us hopeful for the development of etiotropic therapy,making it possible to correct the CFTR mutation causingmucoviscidosis and, through that, improve the quality of life and lifeexpectancy of CF patients.